Global Biodegradable Vascular Stents Market Outlook
Revenue, 2024
$1.1B
Forecast, 2034
$2.6B
CAGR, 2025 - 2034
9.4%
The Biodegradable Vascular Stents industry revenue is expected to be around $1.1 billion in 2025 and expected to showcase growth with 9.4% CAGR between 2025 and 2034. The biodegradable vascular stents market has progressed from its conceptual stage to become a leading segment in interventional cardiology because of increasing coronary artery disease, aging populations and the transition toward minimally invasive durable outcomes. The medical community supports the potential of vessel restoration through non permanent implants because it leads to shorter dual antiplatelet therapy and reduced late complications.The combination of polymer chemistry advancements with magnesium alloy development, drug eluting coating improvements, PCI guidelines and imaging support has strengthened clinical trust in these technologies.
Bioresorbable scaffolds function as biodegradable vascular stents which provide short term luminal support and local drug delivery before they dissolve through hydrolysis or corrosion to restore vascular physiology. The devices feature thin struts, sirolimus class antiproliferative coatings and degradation kinetics that control the balance between radial strength and healing. The medical application of these devices focuses on coronary artery disease and specific peripheral lesions which primarily benefit younger patients.
Market Key Insights
- The Biodegradable Vascular Stents market is projected to grow from $1.1 billion in 2024 to $2.6 billion in 2034. This represents a CAGR of 9.4%, reflecting rising demand across Coronary artery disease (PCI) and Peripheral artery disease (femoropopliteal/BTK).
- Abbott, BIOTRONIK, Elixir Medical are among the leading players in this market, shaping its competitive landscape.
- U.S. and China are the top markets within the Biodegradable Vascular Stents market and are expected to observe the growth CAGR of 6.9% to 9.9% between 2024 and 2030.
- Emerging markets including Indonesia, Brazil and Indonesia are expected to observe highest growth with CAGR ranging between 9.0% to 11.8%.
- Transition like Vessel Restoration via Bioresorbable Platforms is expected to add $61 million to the Biodegradable Vascular Stents market growth by 2030.
- The Biodegradable Vascular Stents market is set to add $1.5 billion between 2024 and 2034, with manufacturer targeting Peripheral interventions & Carotid interventions Applications projected to gain a larger market share.
- With Shift toward minimally invasive cardiology solutions, and Advancements in bioresorbable polymer stent technology., Biodegradable Vascular Stents market to expand 146% between 2024 and 2034.
Opportunities in the Biodegradable Vascular Stents
Public hospitals choose technologies that decrease repeat procedures and downstream costs because CONITEC evaluations prioritize value. Bioresorbable coronary scaffolds provide future surgical possibilities while preventing metal related complications that last long term which matches SUS quality standards. The Southeast and Northeast corridors will also experience the fastest growth in sirolimus eluting PLLA coronary scaffold adoption because of ANVISA registrations and optimized tenders with regional distributors and multicenter outcomes studies that enhance cost effectiveness dossiers.
Growth Opportunities in North America and Asia-Pacific
The market for biodegradable vascular stents expands because of a mature interventional cardiology ecosystem combined with high coronary artery disease prevalence and hospital requirements for innovative devices that reduce long term restenosis risk. The market opportunities exist in next generation bioresorbable scaffolds with thinner struts and magnesium alloys and improved deliverability for complex lesions and peripheral vascular disease indications. The FDA Breakthrough designations together with real world registries drive evidence development while consolidated hospital purchasing and GPOs need strong healtheconomic data. The competitive landscape consists of global leaders and venture backed startups who continue to improve PLLA and magnesium designs through strategic partnerships and physician training and KOL led trials which drive adoption.
The region will experience above average bioresorbable stent adoption because of fast PCI growth and positive demographics and increasing catheterization lab capacity especially in region's with challenging lifetime dual antiplatelet therapy requirements. The market offers three main opportunities which include local manufacturing and value engineered platforms for tender markets and magnesium or PLLA devices designed for Asian anatomies small vessels. The Japan PMDA and China NMPA regulatory momentum together with HTA pathways in Australia and South Korea facilitate market entry but reimbursement variability continues to exist. The market faces intense competition because domestic champions and multinational OEMs fight for market share through clinical evidence and distribution depth and physician education programs.
Market Dynamics and Supply Chain
01
Driver: Rising complex coronary and peripheral lesions and value based care pressures accelerate biodegradable vascular stent adoption
The increasing number of long calcified and small vessel lesions in diabetic and peripheral artery disease patients leads interventionalists to choose temporary scaffolds which promote endothelial healing and restore vasomotion and decrease late stent thrombosis; also advances in ultrathin struts and optimized sirolimus elution and OCT/IVUS guided sizing improve performance in these anatomies. Third, value based care and bundled payments reward fewer repeat procedures and lower lifetime costs; healtheconomic models and real world registries indicate bioresorbable stents can also cut target lesion revascularization beyond year two, strengthening hospital procurement cases and payer coverage rationales.
The development of new materials has also led to the creation of scaffolds that degrade at specific rates while becoming easier to deliver. Stereocomplex PLLA and tyrosinederived polycarbonates provide radial strength and reduced inflammation while maintaining drug release profiles that support consistent late lumen gain. Rareearth magnesium alloys with grain refinement and surface passivation through microarc oxidation techniques slow down corrosion to maintain mechanical stability during healing processes. The technological advancements allow for thinner strut designs which reduce thrombogenicity and improve crossing profiles thus expanding treatment possibilities and strengthening medical professional trust in future bioresorbable vascular scaffolds.
02
Restraint: Clinical safety concerns and evidence gaps
The thicker struts of biodegradable vascular stents continue to raise concerns about late scaffold thrombosis and restenosis risk and deliverability in complex lesions which reduce cardiologist confidence and slow down procedural adoption. The combination of increased regulatory oversight and past notable product recalls has led to stricter trial requirements and longer approval processes that result in conservative guidelines and hospital value analysis committee decisions. The reimbursement policies of payers restrict coverage to specific patient groups while demanding registry data which restricts standard use of these devices and maintains their usage below drug eluting stent levels. The current market situation extends the time until demand peaks while decreasing tender success rates which drives procurement toward established metallic DES systems in major treatment centers.
03
Opportunity: Endovascular interventions for diabetic peripheral artery disease patients in Indias tier two cities and High risk elderly cardiac patients in Japan requiring temporary vessel support during PCI
The increasing diabetes cases in India together with late PAD diagnosis create a growing need for below the knee revascularization procedures in underserved tier two cities. The biodegradable scaffolds maintain vessel patency through their ability to dissolve without creating permanent metal structures that would make future procedures more complicated. The market will experience its highest expansion through magnesium based bioresorbable peripheral stents used for tibial and peroneal vessels because of Ayushman Bharat coverage and CDSCO approvals and cath lab partnerships and training programs that decrease hesitancy and create standardized procedures.
The aging population of Japan along with its high bleeding risk profiles force cardiologists to reduce dual antiplatelet exposure while maintaining future treatment options. Bioresorbable stents function as temporary support devices which restore vessel health through long term processes when used with IVUS/OCT imaging systems. The strongest adoption of thin strut sirolimus eluting bioresorbable coronary scaffolds will occur in university and flagship hospitals through MHLW reimbursement categories and trials with imaging leaders and rigorous post market registries.
04
Challenge: Cost, reimbursement, and competitive pressure
The combination of high device expenses with premium DES and the requirement for OCT/IVUS guidance and extended procedure duration creates episode of care expenses which value based purchasing models struggle to support. The reimbursement systems across markets show inconsistent patterns while payers need long term results to prove cost effectiveness which results in limited coverage and selective hospital formulary adoption. Bioresorbable stents usually end up in specific indications or young low risk patients during competitive tenders because procurement teams select the lowest total cost and most predictable outcomes which reduces the immediate market potential. The price sensitivity in emerging markets together with established DES performance advantages create adoption curves that are compressed and reduce near term demand growth.
Supply Chain Landscape
1
Biomaterials Supply
EvonikCorbionLuxfer MEL Technologies
2
Device Manufacturing
BiotronikMeril Life SciencesAbbott Vascular
3
Sterilization & Packaging
STERIS ASTSterigenicsDuPont
4
Distribution & Clinical Use
Cardinal HealthOwens & MinorCardiac Catheterization Labs
1
Biomaterials Supply
EvonikCorbionLuxfer MEL Technologies
2
Device Manufacturing
BiotronikMeril Life SciencesAbbott Vascular
3
Sterilization & Packaging
STERIS ASTSterigenicsDuPont
4
Distribution & Clinical Use
Cardinal HealthOwens & MinorCardiac Catheterization Labs
Use Cases of Biodegradable Vascular Stents in Coronary artery disease (PCI) & Peripheral artery disease (femoropopliteal/BTK)
Coronary artery disease (PCI) : The deployment of drug eluting bioresorbable vascular scaffolds BRS through standard percutaneous coronary intervention creates scaffolds for de novo coronary lesions which then dissolve over time. The treatment method enables vasomotion recovery while reducing the chance of very late stent thrombosis and maintains future bypass and imaging capabilities through its metal free design. The Magmaris CE marked product from BIOTRONIK stands as the market leader while Merils Me Res100 provides thin strut everolimus delivery, value positioning, Abbott brings global scale and next generation research & development capabilities.
Peripheral artery disease (femoropopliteal/BTK) : The endovascular delivery of drug-eluting bioresorbable scaffolds for peripheral artery disease uses biodegradable polymers such as PLLA platforms and emerging magnesium designs to support femoropopliteal or below-the-knee vessels after angioplasty. These temporary scaffolding systems reduce chronic metal fatigue and fracture, while allowing natural vessel remodeling and preserving options for future bypass or repeat interventions. Abbott continues to advance the Esprit BTK program through its extensive clinical infrastructure, REVA Medical’s Motiv sirolimus BRS benefits from FDA Breakthrough status and polymer expertise, and Meril is gaining momentum in cost-sensitive markets.
Recent Developments
The interest in biodegradable vascular stents has increased because of resorbable magnesium scaffolds and thinner strut PLLA sirolimus eluting designs and manufacturing improvements that increase radial strength and predictable resorption. Device firms partner with OCT/IVUS imaging and polymer experts through strategic collaborations while investors fund precision laser micromachining and degradable coatings and major companies perform selective tuck ins and licensing to expand their intellectual property.
October 2024 : BIOTRONIK unveiled fresh clinical data about its Magmaris bioresorbable magnesium scaffold at TCT 2024 which demonstrated continued safety and effectiveness in modern PCI procedures.
May 2024 : MicroPort MedTech presented updated FIRESORB fully bioresorbable coronary scaffold results at EuroPCR 2024 while discussing its commercialization strategy for China and specific international markets.
October 2023 : The REVA Medical company presented extended follow up data from its Fantom Encore bioresorbable scaffold program at TCT 2023 while announcing strategic plans to restart and expand its BRS product line.
Impact of Industry Transitions on the Biodegradable Vascular Stents Market
As a core segment of the Medical Device industry,
the Biodegradable Vascular Stents market develops in line with broader industry shifts.
Over recent years, transitions such as Vessel Restoration via Bioresorbable Platforms and OutcomeDriven Evidence and ValueBased Uptake have redefined priorities
across the Medical Device sector,
influencing how the Biodegradable Vascular Stents market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Vessel Restoration via Bioresorbable Platforms
The market transition from permanent metal scaffolds to resorbable drug eluting systems made from PLLA and magnesium occurs because BDS restore natural vasomotion after controlled degradation. The market transformation requires manufacturing to adopt precision extrusion and lasercutting and biaxial orientation and GMP/ISO 13485 polymer supply chains to reduce thrombosis risk and enhance outcomes. A specialty biopolymer supplier that produces medical grade PLLA has secured multiple year contracts for coronary stents and resorbable orthopedic screws which drives industry wide adoption and unified quality standards. This industry transition is expected to add $61 million in the industry revenue between 2024 and 2030.
02
OutcomeDriven Evidence and ValueBased Uptake
The development of bioresorbable scaffolds has led to a shift in adoption toward realworld evidence and AIassisted intravascular imaging and riskstratified patient selection which aligns with valuebased care and outcomesbased contracts. The regulatory focus now centers on strong PMCF and registries and extended followup periods because of FDA Breakthrough and EU MDR requirements which drives analytics vendors and hospital cathlab systems to implement longitudinal tracking capabilities. A national payers pilot program for reimbursement based on late lumen patency and reduced repeat PCI has motivated health IT firms to develop crossdevice registries which structural heart programs also utilize.